Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155870 | 0.85 | CYP4F2 (0.44) | MCHR1CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL1366940 | 0.85 | CYP4F2 (0.46) | MCHR1CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL15111078 | 0.83 | MCHR1 (0.45) | MCHR1CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL1366880 | 0.82 | CYP4F2 (0.51) | MCHR1CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL4046867 | 0.78 | CYP4F2 (0.45) | MCHR1CYP4F2CYP4A11 | |
| SCHEMBL158142 | 0.78 | CYP4F2 (0.45) | MCHR1CYP4F2CYP4A11 | |
| SCHEMBL1366609 | 0.76 | CYP4F2 (0.46) | MCHR1CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL1364562 | 0.76 | MCHR1 (0.44) | MCHR1CYP4F2CYP4A11 | |
| SCHEMBL1365511 | 0.76 | MCHR1 (0.44) | MCHR1CYP4F2CYP4A11 | |
| SCHEMBL15238669 | 0.75 | MCHR1 (0.45) | MCHR1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637501-B2 | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637501-B2 | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2448585-B1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2448585-A1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110003793-A1 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2011003005-A1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003793-A1 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, HTR1E | MCHR1 1/4885CYP4F2 1215/4885CYP4A11 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.